Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double blinded, randomized, Priorix- and placebo-controlled, trial to evaluate the optimal dose of MV-CHIK vaccine (against Chikungunya virus) in regard to immunogenicity, safety and tolerability in healthy volunteers

Next Previous
X
Search
Trial Profile

Double blinded, randomized, Priorix- and placebo-controlled, trial to evaluate the optimal dose of MV-CHIK vaccine (against Chikungunya virus) in regard to immunogenicity, safety and tolerability in healthy volunteers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chikungunya virus vaccine (Primary) ; Measles mumps and rubella virus vaccine-(Priorix)
  • Indications Chikungunya virus infections
  • Focus Pharmacodynamics
  • Sponsors Themis Bioscience

    • Most Recent Events

    • 12 Dec 2019 Results of an analysis of humoral immune responses in chikungunya virus infected patients and healthy individuals from this study vaccinated with a candidate CHIKV vaccine published in the Journal of Infectious Diseases.
    • 05 Nov 2018 Primary endpoint (Immunogenicity on day 56 confirmed by plaque reduction neutralization test (PRNT50)) has been met across all treatment group, according to a Themis Bioscience media release.
    • 05 Nov 2018 Results presented in the Themis Bioscience media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top